Monopar Therapeutics (MNPR) Free Cash Flow Growth (5y) (2022 - 2025)

Monopar Therapeutics (MNPR) Free Cash Flow Growth (5y) (2022 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Monopar Therapeutics 824.64 Mn 762.80 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 -22.12%
Sep 30, 2025 -9.96%
Jun 30, 2025 -1.59%
Mar 31, 2025 -38.15%
Dec 31, 2024 -24.48%
Sep 30, 2024 -11.85%
Jun 30, 2024 -17.78%
Mar 31, 2024 -10.70%
Dec 31, 2023 -24.38%
Sep 30, 2023 -26.47%
Jun 30, 2023 -22.79%
Mar 31, 2023 -22.93%
Dec 31, 2022 -9.79%
Sep 30, 2022 -12.45%
Jun 30, 2022 -33.85%
Mar 31, 2022 -51.27%